Climara

In the US, Climara (estradiol systemic) is a member of the drug class estrogens and is used to treat Atrophic Urethritis, Atrophic Vaginitis, Hypoestrogenism, Oophorectomy, Osteoporosis, Postmenopausal Symptoms and Primary Ovarian Failure.

US matches:

• Climara


• Climara Pro


• Climara Pro Weekly Patch


• Climara Weekly Patch


• Climara Pro topical patches

Ingredient matches for Climara

Estradiol

Estradiol is reported as an ingredient of Climara in the following countries:

• Australia


• Canada


• Denmark


• Estonia


• Ireland


• Lithuania


• Luxembourg


• New Zealand


• Norway


• Philippines


• Poland


• Portugal


• Romania


• Serbia


• Slovakia


• Slovenia


• Switzerland


• Taiwan


• Thailand


• Turkey


• United States

Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Climara in the following countries:

• Austria


• Belgium


• Bulgaria


• Czech Republic


• Finland


• France


• Italy


• Latvia


• Netherlands


• South Africa


• Switzerland

International Drug Name Search

Riacetamid

Riacetamid may be available in the countries listed below.

Ingredient matches for Riacetamid

Sulfacetamide Sodium

Sulfacetamide is reported as an ingredient of Riacetamid in the following countries:

• Oman

International Drug Name Search

Gablofen

Gablofen is a brand name of baclofen, approved by the FDA in the following formulation(s):

GABLOFEN (baclofen - injectable; intrathecal)

• 
  Manufacturer: CNS THERAPS INC
  
  Approval date: November 19, 2010
  
  Strength(s): 0.05MG/ML ^[AP], 0.5MG/ML ^[AP], 2MG/ML ^[AP]

Has a generic version of Gablofen been approved?

No. There is currently no therapeutically equivalent version of Gablofen available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gablofen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Gablofen.

See also...

• Gablofen Consumer Information (Drugs.com)
• Gablofen Consumer Information (Wolters Kluwer)
• Gablofen Advanced Consumer Information (Micromedex)
• Baclofen Consumer Information (Drugs.com)
• Baclofen Consumer Information (Wolters Kluwer)
• Baclofen Tablets Consumer Information (Wolters Kluwer)
• Baclofen Consumer Information (Cerner Multum)
• Baclofen Advanced Consumer Information (Micromedex)
• Baclofen Intrathecal Advanced Consumer Information (Micromedex)
• Baclofen AHFS DI Monographs (ASHP)

Neozine

Neozine may be available in the countries listed below.

Ingredient matches for Neozine

Levomepromazine

Levomepromazine maleate (a derivative of Levomepromazine) is reported as an ingredient of Neozine in the following countries:

• Brazil

International Drug Name Search

Duricef

Generic Name: Cefadroxil
Class: First Generation Cephalosporins
CAS Number: 66592-87-8

Introduction

Antibacterial; β-lactam antibiotic; first generation cephalosporin.^a

Uses for Duricef

Pharyngitis and Tonsillitis

Treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci).^{100 120 121} Generally effective in eradicating S. pyogenes from the nasopharynx, but efficacy in prevention of subsequent rheumatic fever has not been established to date.^{100 120 121}

CDC, AAP, IDSA, AHA, and others recommend oral penicillin V or IM penicillin G benzathine as treatments of choice;^{116 117 118 119} oral cephalosporins and oral macrolides considered alternatives.^{116 117 118 119} Amoxicillin sometimes used instead of penicillin V, especially for young children.^{116 119}

Skin and Skin Structure Infections

Treatment of mild to moderate skin and skin structure infections caused by susceptible staphylococci or streptococci.^{100 120 121}

Urinary Tract Infections (UTIs)

Treatment of mild to moderate UTIs, include acute prostatitis, caused by susceptible Escherichia coli, Klebsiella, or Proteus mirabilis.^{100 120 121}

Prevention of Bacterial Endocarditis

Alternative for prevention of α-hemolytic (viridans group) streptococcal endocarditis† in penicillin-allergic individuals undergoing certain dental or upper respiratory tract procedures who have cardiac conditions that put them at highest risk.^{115 116} Should not be used in those with immediate-type penicillin hypersensitivity (see Cross-hypersensitivity under Cautions).¹¹⁵

When selecting anti-infectives for prophylaxis of bacterial endocarditis, consult most recent AHA recommendations for specific information on which cardiac conditions are associated with highest risk of endocarditis and which procedures require prophylaxis.¹¹⁵

Duricef Dosage and Administration

Administration

Oral Administration

Administer orally.^{100 120 121}

May be given without regard to meals;^{100 120 121} administration with food may minimize adverse GI effects.^{100 120 121}

Dosage

Available as the monohydrate; dosage expressed as cefadroxil.¹⁰⁰

Pediatric Patients

General Pediatric Dosage

Oral

AAP recommends 30 mg/kg daily in 2 equally divided doses for treatment of mild or moderately severe infections in children ≥1 month of age.¹¹⁶ AAP states the drug is inappropriate for treatment of severe infections.¹¹⁶

Pharyngitis and Tonsillitis

Oral

30 mg/kg daily given as a single dose or in 2 equally divided doses for ≥10 days.^{100 120 121}

Skin and Skin Structure Infections

Impetigo

Oral

30 mg/kg daily given as a single dose or in 2 equally divided doses.^{100 120 121}

Other Skin and Skin Structure Infections

Oral

30 mg/kg daily given in 2 equally divided doses.^{100 120 121}

Urinary Tract Infections (UTIs)

Oral

30 mg/kg daily given in 2 equally divided doses.^{100 120 121}

Prevention of Bacterial Endocarditis†

Patients Undergoing Certain Dental or Upper Respiratory Tract Procedures†

Oral

50 mg/kg (up to 2 g) as a single dose given 1 hour prior to the procedure.¹¹⁶

Adults

Pharyngitis and Tonsillitis

Oral

1 g daily given as a single dose or in 2 divided doses for 10 days.^{100 120 121}

Skin and Skin Structure Infections

Oral

1 g daily given as a single dose or in 2 divided doses.^{100 120 121}

Urinary Tract Infections (UTIs)

Uncomplicated Lower UTIs (e.g., Cystitis)

Oral

1 or 2 g daily given as a single dose or in 2 divided doses.^{100 120 121}

Other UTIs

Oral

2 g daily given in 2 divided doses.^{100 120 121}

Prevention of Bacterial Endocarditis†

Patients Undergoing Certain Dental or Upper Respiratory Tract Procedures†

Oral

2 g as a single dose given 1 hour prior to the procedure.¹¹⁶

Special Populations

Renal Impairment

Dosage adjustments required if Cl_cr ≤50 mL/minute per 1.73 m².^{100 120 121} Use an initial 1-g induction dose followed by 500-mg maintenance doses given at intervals based on the degree of renal impairment.^{100 120 121} (See Table.)

Adult Dosage in Renal Impairment100120121

Clcr (mL/min per 1.73 m2)	Induction Dose	Maintenance Dosage
25–50	1 g	500 mg every 12 hours
10–25	1 g	500 mg every 24 hours
0–10	1 g	500 mg every 36 hours

Geriatric Patients

No dosage adjustments except those related to renal impairment.^a Cautious dosage selection because of age-related decreases in renal function.^a (See Renal Impairment under Dosage and Administration.)

Cautions for Duricef

Contraindications

• 
  

  Known hypersensitivity to cefadroxil or other cephalosporins.^{100 120 121}

  
  

Warnings/Precautions

Warnings

Superinfection/Clostridium difficile-associated Diarrhea and Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi with prolonged use.^{100 120 121} Close observation of the patient is essential.^{100 120 121} Institute appropriate therapy if superinfection occurs.^{100 120 121}

Treatment with anti-infectives may permit overgrowth of Clostridium difficile.^{100 120 121} Clostridium difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) has been reported with nearly all anti-infectives, including cefadroxil, and may range in severity from mild diarrhea to fatal colitis.¹⁰⁰

Consider CDAD if diarrhea develops and manage accordingly.^{100 120 121} Careful medical history is necessary since CDAD has been reported to occur as late as 2 months or longer after anti-infective therapy is discontinued.¹⁰⁰

If CDAD is suspected or confirmed, the anti-infective may need to be discontinued.¹⁰⁰ Some mild cases may respond to discontinuance alone.^{100 120 121 a} Manage moderate to severe cases with fluid, electrolyte, and protein supplementation, anti-infective therapy active against C. difficile (e.g., oral metronidazole or vancomycin), and surgical evaluation when clinically indicated.^{100 120 121 a}

Sensitivity Reactions

Hypersensitivity Reactions

Possible hypersensitivity reactions (e.g., urticaria, pruritus, rash, fever and chills, eosinophilia, joint pain or inflammation, edema, erythema, genital and anal pruritus, angioedema, shock, hypotension, vasodilatation, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, exfoliative dermatitis, anaphylaxis).^{100 120 121 a}

If a hypersensitivity reaction occurs, discontinue cefadroxil immediately and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, and maintenance of an adequate airway and oxygen).^{100 120 121 a}

Cross-hypersensitivity

Partial cross-sensitivity among cephalosporins and other β-lactam antibiotics, including penicillins and cephamycins.^{100 120 121 a}

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs.^{100 120 121 a} Cautious use recommended in patients with a history of hypersensitivity to penicillins:^{100 120 121} avoid use in those who have had an immediate-type (anaphylactic) hypersensitivity reaction^{104 a} and administer with caution in those who have had a delayed-type (e.g., rash, fever, eosinophilia) reaction.^a

General Precautions

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of cefadroxil and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.¹⁰⁰

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.¹⁰⁰ In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.¹⁰⁰

History of GI Disease

Use cephalosporins with caution in patients with a history of GI disease, particularly colitis.^{100 120 121 a} (See Superinfection/Clostridium difficile-associated Diarrhea and Colitis under Cautions.)

Coombs' Test Results

Positive direct Coombs’ test results reported with cephalosporins.^{100 120 121 a} This may interfere with certain hematologic studies or transfusion cross-matching procedures.^{100 120 121 a} May also cause positive Coombs’ tests in neonates whose mothers received a cephalosporin prior to delivery.^{100 120 121 a}

Specific Populations

Pregnancy

Category B.^{100 120 121}

Lactation

Cephalosporins generally distributed into milk.^a Use with caution.^{100 120 121}

Geriatric Use

Safety and efficacy in those ≥65 years of age similar to that in younger adults, but possibility exists of greater sensitivity to the drug in some geriatric patients.^{100 121}

Substantially eliminated by kidneys and dosage adjustments are necessary in patients with impaired renal function.^{100 120 121} Select dosage with caution and assess renal function periodically because of age-related decreases in renal function.^{100 120 121} (See Renal Impairment under Dosage and Administration.)

Renal Impairment

Decreased clearance and increased half-life.^{100 120}

Use with caution in those with markedly impaired renal function.^{100 120 121} Monitor closely and assess renal function prior to and during therapy.^{100 120 121}

Reduce dosage in those with Cl_cr ≤50 mL/minute.^{100 120 121} (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Dyspepsia, nausea, vomiting.^{100 120 121}

Duricef Pharmacokinetics

Absorption

Bioavailability

Rapidly and almost completely absorbed from GI tract.^{100 101 102 103 104 105 106} Peak serum concentrations attained within 1–2 hours.^{101 102 103 104 105 106 107 108 109 110 111 112 113}

Food

Food does not affect absorption.^{100 102 107 108 109}

Distribution

Extent

Cephalosporins widely distributed into tissues and fluids.^a

Plasma Protein Binding

20%.^a

Elimination

Metabolism

Not appreciably metabolized.¹⁰⁰

Elimination Route

≥70% of a dose excreted unchanged in urine.^{100 101 102 103 104 105 106 107 110 111 112 113}

Half-life

1.1–2 hours in adults with normal renal function.^{103 105 107 108 110 111 112}

Special Populations

Clearance is decreased and half-life increased in patients with renal impairment.^{105 114}

Half-life is 2.5–8.5 hours in those with Cl_cr 20–50 mL/minute per 1.73 m² and 13.3–25.5 hours in those with Cl_cr < 20 mL/minute per 1.73 m².¹¹⁴

Stability

Storage

Oral

Capsules and Tablets

15–30°C in tight container.^{100 120}

For Suspension

15–30°C.¹⁰⁰ After reconstitution, refrigerate in a tight container and discard after 14 days.^{100 121}

Actions and SpectrumActions

• 
  

  First generation cephalosporin with a limited spectrum of activity compared with second and third generation cephalosporins.^a

  
  


• 
  

  Usually bactericidal.^{100 a}

  
  


• 
  

  Like other β-lactam antibiotics, antibacterial activity results from inhibition of bacterial cell wall synthesis.^{100 a}

  
  


• 
  

  In vitro spectrum of activity includes some gram-positive aerobic bacteria and some gram-negative aerobic bacteria.^{100 a} Inactive against anaerobic bacteria, fungi, and viruses.^a

  
  


• 
  

  Gram-positive aerobes: active in vitro and in clinical infections against staphylococci (including penicillinase-producing strains), Streptococcus pyogenes (group A β-hemolytic streptococci), and S. pneumoniae.^{100 a} Oxacillin-resistant staphylococci (methicillin-resistant staphylococci) and most enterococci are resistant.^{100 a}

  
  


• 
  

  Gram-negative aerobes: active in vitro and in clinical infections against Moraxella catarrhalis, Escherichia coli, Klebsiella, and Proteus mirabilis.^{100 a} Inactive against Acinetobacter, Enterobacter, Morganella morganii, P. vulgaris, and Pseudomonas.^{100 a}

  
  

Advice to Patients

• 
  

  Advise patients that antibacterials (including cefadroxil) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).¹⁰⁰

  
  


• 
  

  Importance of completing full course of therapy, even if feeling better after a few days.¹⁰⁰

  
  


• 
  

  Advise patients that skipping doses or not completing the full course of therapy may decrease effectiveness and increase the likelihood that bacteria will develop resistance and will not be treatable with cefadroxil or other antibacterials in the future.¹⁰⁰

  
  


• 
  

  Advise patients that diarrhea is a common problem caused by anti-infectives and usually ends when the drug is discontinued.¹⁰⁰ Importance of contacting a clinician if watery and bloody stools (with or without stomach cramps and fever) occur during or as late as 2 months or longer after the last dose.¹⁰⁰

  
  


• 
  

  Importance of discontinuing therapy and informing clinician if an allergic reaction occurs.^{100 120 121}

  
  


• 
  

  Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs as well as any concomitant illnesses.^{100 120 121}

  
  


• 
  

  Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.^{100 120 121}

  
  


• 
  

  Importance of informing patients of other important precautionary information.^{100 120 121} (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Cefadroxil

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Capsules	500 mg*	Cefadroxil Capsules	Ranbaxy, Sandoz, Teva
	For suspension	250 mg/5 mL*	Cefadroxil for Suspension	Ranbaxy
			Duricef	Warner-Chilcott
		500 mg/5 mL*	Cefadroxil for Suspension	Ranbaxy
			Duricef	Warner-Chilcott
	Tablets	1 g*	Cefadroxil Tablets	Ranbaxy, Teva

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Cefadroxil 1GM Tablets (TEVA PHARMACEUTICALS USA): 30/$139.99 or 60/$279.98

Cefadroxil 500MG Capsules (TEVA PHARMACEUTICALS USA): 30/$34.99 or 60/$69.98

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions March 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

Only references cited for selected revisions after 1984 are available electronically.

100. Warner Chilcott. Duricef (cefadroxil monohydrate) prescribing information. Rockaway, NJ. 2007 Apr.

101. Hartstein AI, Patrick KE, Jones SR et al. Comparison of pharmacological and antimicrobial properties of cefadroxil and cephalexin. Antimicrob Agents Chemother. 1977; 12:93-7. [PubMed 883822]

102. Lode VH, Stahlmann R, Dzwillo G et al. Vergleichende Pharmakokinetik oraler Cephalosporine: Cephalexin, Cefaclor und Cefadroxil. (German; with English abstract.) Arzneim-Forsch. 1980; 30:505-9.

103. Marino EL, Dominguez-Gil A. Influence of dose on the pharmacokinetics of cefadroxil. Eur J Clin Pharmacol. 1980; 18:505-9. [IDIS 126977] [PubMed 7461017]

104. Marino EL, Dominguez-Gil A, Muriel C. Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil. Int J Clin Pharmacol Ther Toxicol. 1982; 20:73-7. [PubMed 7061182]

105. Humbert G, Leroy A, Fillastre JP et al. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Infection. 1980; 8(Suppl 5):S598-602.

106. Hampel B, Lode H, Wagner J et al. Pharmacokinetics of cefadroxil and cefaclor during an eight-day dosage period. Antimicrob Agents Chemother. 1982; 22:1061-3. [IDIS 161996] [PubMed 7159069]

107. Pfeffer M, Jackson A, Ximenes J et al. Comparative human oral clinical pharmacology of cefadroxil, cephalexin, and cephradine. Antimicrob Agents Chemother. 1977; 11:331-8. [IDIS 82078] [PubMed 848940]

108. Lode H, Stahlmann R, Koeppe P. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother. 1979; 16:1-6. [PubMed 475366]

109. Ginsburg CM, McCracken GH, Clahsen JC et al. Clinical pharmacology of cefadroxil in infants and children. Antimicrob Agents Chemother. 1978; 13:845-8. [PubMed 666305]

110. La Rosa F, Ripa S, Prenna M et al. Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob Agents Chemother. 1982; 21:320-2. [IDIS 146663] [PubMed 7073267]

111. Simon VC. Zur Pharmakokinetik von Cefadroxil, einem neuen Oral-Cephalosporin. (German; with English abstract.) Arzneim-Forsch. 1980; 30:502-4.

112. Welling PG, Selen A, Pearson JG et al. A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures. Biopharm Drug Dispos. 1985; 6:147-57. [IDIS 200635] [PubMed 4005394]

113. Adam D, Gierschik P. Vergleichende Untersuchungen zur Pharmakokinetik von Cefadroxil und Amoxicillin nach oraler Nuchterngabe. (German; with English abstract.) Infection. 1980; 8(Suppl 5):S567-72.

114. Cutler RE, Blair AD, Kelly MR. Cefadroxil kinetics in patients with renal insufficiency. Clin Pharmacol Ther. 1979; 25:514-21. [IDIS 97087] [PubMed 436355]

115. Wilson W, Taubert KA, Gewitz M et al. Prevention of infective endocarditis. Guidelines from the American Heart Association. A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Apr 19. (Epub ahead of print).

116. American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:754,834.

117. Dajani A, Taubert K, Ferrieri P et al and the American Heart Association Committee on Rheumatic Fever et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: a statement for health professionals. Pediatrics. 1995; 96:758-64. [IDIS 355409] [PubMed 7567345]

118. Cooper RJ, Hoffman JR, Bartlett JG et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med. 2001; 134:509-17. [IDIS 460578] [PubMed 11255530]

119. Bisno AL, Gerber MA, Gwaltney JM et al et al. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clin Infect Dis. 1997; 25:574-83. [PubMed 9314443]

120. Ranbaxy. Cefadroxil tablets and capsules USP prescribing information. Princeton, NJ. 2002 May.

121. Ranbaxy. Cefadroxil for oral suspension, USP prescribing information. Princeton, NJ. 2003 Nov.

a. AHFS Drug Information 2003. McEvoy GK, ed. Cephalosporins General Statement. American Society of Health-System Pharmacists; 2003:125-39.

More Duricef resources

• Duricef Side Effects (in more detail)
• Duricef Use in Pregnancy & Breastfeeding
• Drug Images
• Duricef Drug Interactions
• Duricef Support Group
• 0 Reviews for Duricef - Add your own review/rating

• Duricef Prescribing Information (FDA)


• Duricef MedFacts Consumer Leaflet (Wolters Kluwer)


• Duricef Concise Consumer Information (Cerner Multum)


• Duricef Advanced Consumer (Micromedex) - Includes Dosage Information


• Cefadroxil Prescribing Information (FDA)


• Cefadroxil Professional Patient Advice (Wolters Kluwer)

Compare Duricef with other medications

• Bacterial Endocarditis Prevention
• Impetigo
• Kidney Infections
• Skin and Structure Infection
• Skin Infection
• Tonsillitis/Pharyngitis
• Upper Respiratory Tract Infection
• Urinary Tract Infection

Lomerizine

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0101477-55-8

Chemical Formula

C27-H30-F2-N2-O3

Molecular Weight

468

Therapeutic Categories

Antimigraine agent

Calcium channel blocker

Vasodilator, cerebral

Chemical Names

1-(2,3,4-trimethoxybenzyl)-4-[bis(4-fluorophenyl)methyl]piperazine

1-(4,4'-Difluorobenzhydryl)-4-(2,3,4-trimethoxybenzyl)piperazine

1-[Bis(p-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine (WHO)

1-[Bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine

Foreign Names

• Lomerizinum (Latin)
• Lomerizine (German)
• Lomérizine (French)
• Lomerizina (Spanish)

Generic Names

• UNII-DEE37CY4VO (IS)
• Lomerizine Hydrochloride (OS: JAN)
• Flometizine hydrochloride (IS)
• KB-2796 (IS)

Brand Names

• Migsis
  Pfizer, Japan



• Terranas
  Schering-Plough, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Norcalcin

Norcalcin may be available in the countries listed below.

Ingredient matches for Norcalcin

Calcitonin

Calcitonin is reported as an ingredient of Norcalcin in the following countries:

• Greece

International Drug Name Search

Neozalkonin

Neozalkonin may be available in the countries listed below.

Ingredient matches for Neozalkonin

Benzalkonium Chloride

Benzalkonium chloride (a derivative of Benzalkonium) is reported as an ingredient of Neozalkonin in the following countries:

• Japan

International Drug Name Search

Turresis

Turresis may be available in the countries listed below.

Ingredient matches for Turresis

Ethambutol

Ethambutol dihydrochloride (a derivative of Ethambutol) is reported as an ingredient of Turresis in the following countries:

• Portugal

International Drug Name Search

Ibuprofene

Ibuprofene may be available in the countries listed below.

Ingredient matches for Ibuprofene

Ibuprofen

Ibuprofene (DCIT) is known as Ibuprofen in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.